Advertisement

Topics

Companies Related to "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment" [Most Relevant Company Matches] - Page: 5 RSS

12:30 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment" found in our extensive corporate database of over 50,000 company records.

Showing "Efficacy Safety Empagliflozin 10773 Patients With Type Diabetes" Companies 101–125 of 5,800+

Relevant

Hygieia, Inc.

Hygieia, Inc. is an emerging diabetes health care company developing new ways to improve the effectiveness of therapy while reducing the cost of diabetes care. Hygieia’s first product is a handheld Diabetes Insulin Guidance System (DIGS™) designed to improve insulin therapy effectiveness for patients. DIGS works in a way that makes it a feasible ...


Adamed Sp. z o.o.

Our priority is production of ethical drugs. We are leaders on the market of new generation drugs in many therapeutic groups such as cardiology, psychiatry, pulmonology, gynecology and treatment of urinal tract infections.We invest in research that is set to find effective and innovative original drugs which can be used for the most common diseases of our time, diabetes, venous thromboembolism (VT...

Mellitus, LLC

Mellitus is dedicated to advancing diabetes detection and monitoring through products based on GCD59, a biomarker of glycemic load that is unique because of its direct relationship to the complications of diabetes. Our premier application is a patient-friendly test for gestational diabetes, enabling more timely intervention to improve the health of both mo...


Update Pharma Inc.

Update Pharma Inc. is developing UPI-928, an agent developed in the 1980’s by Lederle Laboratories in 44 phase 1, 2 and 3 clinical trials, including 33 clinical trials at the National Cancer Institute. Despite an acceptable safety database of over 2,000 treated patients, over 70 peer reviewed clinical publications that demonstrated efficacy in leukemi...

NeuroTherapeutics Pharma, Inc.

NeuroTherapeutics Pharma is a privately held life sciences company which is focused on the discovery and development of novel therapeutics for patients suffering from CNS disorders. The company is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action which is unlike that of any marketed ...

Sciele Pharma

Sciele Pharma, Inc. (NASDAQ:SCRX), formerly known as First Horizon Pharmaceutical Corp., is a pharmaceutical company specializing in sales, marketing, and the development of branded prescription products focused on Cardiovascular/Metabolic and Women’s Health. The Company’s cardiovascular/metabolic products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina,...

Diamyd Medical AB

Founded in 1996, Diamyd Medical AB (OMXS: DIAM B) (OTCBB: DMYDY), is an emerging and global biotechnology company based in Stockholm, Sweden and Pittsburgh, PA, USA. Diamyd Medical is focused on developing treatments for diabetes, both Type 1 and Type 2, via GAD protein therapy. Its lead drug candidate, Diamyd™, is designed to reduce the need of insulin injections and prevent the destruction of ...

Telephus Medical LLC

Telephus Medical, located in San Diego, California, is developing a suite of monoclonal antibody products designed to neutralize key staphylococcal enzymes used to attach to host tissues, replicate and evade immune attack. These enzymes, are central components of the bacterial machinery staphylococci utilize to invade host tissues, evade the immune respons...

Patient Safety Movement Foundation and The International Society for Quality in Health Care

More than 200,000 people die every year in U.S. hospitals and 4.8 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation is a global non-profit which creates free tools for patients and hospitals. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovat...

PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and le...

Santarus, Inc.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists, endocrinologists and other physicians. The company’s current commercial efforts are focused on GLUMETZA® (metformin HCl extended release tablets), which ...

TransTech Pharma, Inc.

TransTech Pharma is a privately held clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of human therapeutics to fill unmet medical needs. The Company’s high-throughput drug discovery platform, Translational Technology®, translates the functional modulation of human proteins into safe and effective me...

Smithers Avanza

Smithers Avanza is a contract research organization known for superior quality, on-time delivery, flexibility, and responsiveness. Our laboratories support the pharmaceutical and chemical industries. At our GLP, cGMP, and AAALAC accredited facilities, our Development Services group offers general toxicology, safety pharmacology, vaccine safety testi...

Medtronic Diabetes

At Medtronic Diabetes, our 20 plus year history vividly reflects our dedication and ongoing vision to develop an "artificial pancreas". In 1983, we pioneered the idea of continuous insulin delivery, introducing our first insulin pump in an effort to find a "better way" to deliver insulin for people with diabetes. Since that time, Medtronic Diabetes has remained the market leader, earning a reputat...

GANYMED Pharmaceuticals AG

GANYMED Pharmaceuticals AG is developing monoclonal antibody therapeutics against solid tumors, where current therapies are poor and where there is an overriding medical need. The therapeutic efficacy of current solid cancer therapeutics is severely limited, because their molecular targets are elevated in a subset of a particular cancer but they are also found widely in normal tissues. In contrast...

Cliffside Malibu

Cliffside Malibu is a full-service residential drug treatment program and alcohol addiction treatment center in the Los Angeles area. At Cliffside, a team of highly trained experts administer individually tailored rehabilitation programs for every type of addiction to patients who place a premium on privacy, safety, and, most importantly, effectiveness. The drug rehabilitation facility gets its ...

Biotech Holdings Ltd

Biotech Holdings Ltd. is an integrated pharmaceutical company based in Vancouver, Canada, engaged in research, development, manufacture and marketing of pharmaceutical products. The focus of the Company is the manufacturing and international marketing of SucanonTM, a new drug for the treatment of Type II Diabetes.

Flex Pharma, Inc.

Flex Pharma, Inc. is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders. Flex Pharma has demonstrated initial human efficacy related to muscle cramping in healthy volunteers. The Company plans to initiate efficacy studies in patients with neuromuscular disorders in the first half of 2015. Additiona...

Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charco...

DARA BioSciences, Inc.

DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND’s (Investigationa...

PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's ...

Tolerx, Inc.

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKli...

Tethys Bioscience, Inc.

Tethys is a cardiometabolic diagnostics company that creates and commercializes breakthrough biomarker-based blood tests that predict imminent disease risk and enable targeted intervention to preempt the onset of chronic conditions such as type 2 diabetes. Tethys introduced its first product -- PreDx® Diabetes Risk Score -- to the market in 2008, and in...

IrriMax Corporation

Founded in 1994, IrriMax® Corporation develops and markets wound irrigation solutions using a patented, innovative delivery method that produces unmatched efficacy and safety. The medical device company’s goal is to improve patient outcomes by treating and preventing infections, as well as to increase the safety of healthcare workers. Its flagship ...

Oxford Medical Diagnostics Ltd

Oxford Medical Diagnostics develops and supplies breath analysis technologies for rapid, accurate, and low-cost monitoring of diseases and metabolic functions. The focus of OMD’s work is the development of a breath test to indirectly measure blood ketones. This test is designed to assist patients with Type 1 diabetes to monitor the management of their condition and its complications. Di...


More From BioPortfolio on "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks